Bymetric
UK company intelligence
Spinout Active LTD

Company profile

Lunac Therapeutics Limited

UK company 11317849, incorporated on 18 April 2018.

LUNAC Therapeutics | Anticoagulant Discovery

LUNAC Therapeutics are a drug discovery spin-out from University of Leeds, developing next generation oral anti-coagulant therapies.

Company number
11317849
Incorporated
18 Apr 2018
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
18 April 2018

Company number 11317849

Verify at Companies House
Legal name
LUNAC THERAPEUTICS LIMITED
Company type
LTD
Region
London
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Jun 2023 to 31 May 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
1

Company events

Reference milestones and recent Companies House filing stream events.

1 event
18 Apr
2018

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

LUNAC Therapeutics develops anti-coagulant drugs to prevent thrombosis.

A virtual company that is seeking investor funding to pursue development of our anticoagulant drug.

Project impact

In early stages but soon will happen!

LUNAC Therapeutics
2018
https://www.lunactherapeutics.com/
LUNAC Therapeutics
2018
https://www.lunactherapeutics.com/
LUNAC THERAPEUTICS LIMITED
2018

Public funding

2 awards
First funded
2019
Funded years
2019, 2020
Age at first award
1 years

Projects

2020 Feasibility Studies Lead participant

Continuity Award of Development of First-in class small molecule preclinical candidate anticoagulant targeting activated factor XII with minimal risk of bleeding -105439

1 Jun 2020 to 30 Nov 2020

Awarded
£249,917
Total cost £249,917

no public description

2019 Collaborative R&D Lead participant

Development of First-In Class Small Molecule Preclinical Candidate Anticoagulant Targeting Activated Factor XII with Minimal Risk of Bleeding

1 Sep 2019 to 31 May 2021

Awarded
£1,610,865
Total cost £2,301,235

Current treatments for patients who have a risk of forming blood clots are effective but carry a significant increase in the risk of bleeding. Anticoagulants taken by mouth include vitamin-K dependent antagonists (e.g. warfarin), direct thrombin inhibitors and FXa inhibitors [Non-vitamin K Oral Anticoagulants (NOACs)]. Studies have shown that NOACs signif...

Product types

Collaborative R&D Feasibility Studies